Supplements

Adding liposomal bupivacaine to bupivacaine hydrochloride for serratus anterior plane block improves pain-related and early recovery outcomes after modified radical mastectomy compared with bupivacaine hydrochloride alone.

This randomized, double-blind trial compares liposomal bupivacaine plus bupivacaine HCl versus bupivacaine HCl alone for serratus anterior plane block in 76 patients undergoing modified radical mastectomy. The primary outcome is the Quality of Recovery-15 score at 24 hours postoperatively, with secondary outcomes including pain intensity up to 72 hours, opioid use, and sleep quality. Results are pending as this is a protocol paper.

Last updated: Jul 15, 2026•1 RCTs•📖 Read as article →

Evidence Score

Evidence Score42/100
Human RCT★★☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Liposomal Bupivacaine for Serratus Anterior Plane Block in Modified Radical Mastectomy: Protocol for a Randomized, Double-Blind Trial Evaluating Pain-Related and Early Recovery Outcomes.

observational

Wei M, Tong J, Pang Y, Zhou X, Qiu Y, Wang Z · Journal of pain research (2026)

Participants: N/A
Duration: Up to 3 months postoperatively
Intervention: Unilateral ultrasound-guided serratus anterior plane block with liposomal bupivacaine plus bupivacaine HCl (Group L) versus bupivacaine HCl alone (Group B), administered after induction of general anesthesia and before skin incision.
Outcome: Quality of Recovery-15 (QoR-15) score at 24 hours postoperatively; secondary outcomes include pain intensity up to 72 hours, opioid use (morphine milligram equivalents), QoR-15 at 48 and 72 hours, time to first PCA demand, Overall Benefit of Analgesia Score, postoperative nausea and vomiting, sleep quality, perioperative complications, and neuropathic pain at 3 months (DN4i).
Effect Size: N/A
Population: Seventy-six patients undergoing elective modified radical mastectomy for breast cancer.

Result:

PubMed: 42438817DOI: 10.2147/JPR.S617864

Mechanism Graph

Liposomal bupivacaine provides sustained release of local anesthetic
↓
Prolongs sensory blockade duration
↓
Reduces nociceptive input from the surgical site
↓
Decreases postoperative pain and opioid consumption, improving early recovery

Limitations

  • ⚠Results are not yet available as this is a protocol paper; no data on efficacy or safety are reported.
  • ⚠Sample size is relatively small (n=76), which may limit generalizability and detection of rare adverse events.

Frequently Asked Questions

What is the primary outcome measured in this trial?▼

The primary outcome is the Quality of Recovery-15 (QoR-15) score at 24 hours postoperatively.

How many patients are enrolled in this study?▼

Seventy-six patients undergoing elective modified radical mastectomy for breast cancer are being enrolled.

What is the difference between the two treatment groups?▼

Group L receives liposomal bupivacaine plus bupivacaine HCl for the serratus anterior plane block, while Group B receives bupivacaine HCl alone.

When were the results of this trial published?▼

This is a protocol paper; results are not yet available. The trial was registered in November 2025 and published in 2026.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Wei M, Tong J, Pang Y, Zhou X, Qiu Y, Wang Z. "Liposomal Bupivacaine for Serratus Anterior Plane Block in Modified Radical Mastectomy: Protocol for a Randomized, Double-Blind Trial Evaluating Pain-Related and Early Recovery Outcomes.." Journal of pain research, 2026. PMID: 42438817 DOI: 10.2147/JPR.S617864
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.